What is the actual selling price of Mitotane in domestic hospital pharmacies?

Mitotane is a targeted drug mainly used to treat adrenocortical cancer. At present, the original drug of mitotane has been launched in China, but due to its short time on the market, the specific pharmacy price has not been widely disclosed. This drug has not yet been included in the national medical insurance catalog, so patients may face higher out-of-pocket expenses when purchasing it from hospital pharmacies or designated channels by pharmaceutical companies. It is recommended to consult the relevant hospitals or pharmacies in advance to obtain accurate price information before purchasing the drug.

According to the sales situation in foreign markets, the common versions of mitotane’s original drug include the European version and the Turkish version, with a specification of 500mg*100 tablets per box. The selling price of such original drugs is usually around 9,000 yuan, but the price will change due to exchange rate fluctuations, channel differences, import procedures and other factors, so the actual purchase price may differ from the market reference price.

For some patients with limited financial conditions, choosing overseas generic drugs with more affordable prices may be an alternative. For example, the generic version of mitotane produced by a Lao pharmaceutical factory also uses 500mg*100 tablets, and its market price is about more than 2,000 yuan. Although these generic drugs are cheaper, you still need to confirm whether their quality and efficacy are stable before choosing, and it is recommended to use them under the guidance of a professional doctor.

Overall, the actual selling price of mitotane in domestic hospital pharmacies is still uncertain. When purchasing the drug, patients should consider it based on their own economic conditions, doctor's advice, and drug accessibility. When not yet included in medical insurance, understanding market prices and alternatives in a timely manner can help patients make more reasonable treatment arrangements and financial planning.

Reference materials:https://go.drugbank.com/drugs/DB00648